Trials / Conditions / Atypical Hemolytic Uremic Syndrome (aHUS)

Atypical Hemolytic Uremic Syndrome (aHUS)

7 registered clinical trials studyying Atypical Hemolytic Uremic Syndrome (aHUS) — 1 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	Study of Ultomiris® (Ravulizumab) Safety in Pregnancy NCT06312644	Alexion Pharmaceuticals, Inc.	—
Active Not Recruiting	A Prospective, Non-interventional, Observational Study of Presentation, Treatment Patterns and Outcomes in Aty NCT06099236	AstraZeneca	—
Completed	Study of Ravulizumab in Children and Adolescents With Atypical Hemolytic Uremic Syndrome (aHUS) NCT03131219	Alexion Pharmaceuticals, Inc.	Phase 3
Completed	Study of ALXN1210 in Complement Inhibitor Treatment-Naïve Adult and Adolescent Participants With Atypical Hemo NCT02949128	Alexion Pharmaceuticals, Inc.	Phase 3
Completed	The Safety and Efficacy of Eculizumab in Japanese Patients With Atypical Hemolytic Uremic Syndrome (aHUS) NCT01757431	Alexion Pharmaceuticals, Inc.	Phase 2
Completed	To Characterize the Safety and Tolerability of Eculizumab in Two Japanese aHUS Patients NCT01755429	Alexion Pharmaceuticals, Inc.	—
Completed	A Retrospective, Observational, Non-interventional Trial to Assess Eculizumab Treatment Effect in Patients Wit NCT01770951	Alexion Pharmaceuticals, Inc.	—